Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261329 | 0.85 | SMN1; SMN2 (0.59) | TYK2POLBKMT2AMAPTERCC5 | |
| SCHEMBL696853 | 0.85 | ALDH1A1 (0.59) | TYK2P2RX7POLBKMT2AP2RY12 | |
| SCHEMBL3142619 | 0.85 | TYK2 (0.55) | TYK2POLBKMT2AMAPTHTT | |
| SCHEMBL11197823 | 0.84 | NPC1 (0.55) | POLBMAPTHTTNPSR1RAB9A | |
| SCHEMBL2850887 | 0.83 | CASP1 (0.55) | TYK2P2RX7POLBKMT2AP2RY12 | |
| Hydrochloric Acid SCHEMBL18861007 | 0.83 | SMN1; SMN2 (0.57) | TYK2POLBKMT2AMAPTERCC5 | |
| SCHEMBL1180024 | 0.83 | KDM4E (0.60) | TYK2P2RX7POLBKMT2AP2RY12 | |
| SCHEMBL2318688 | 0.81 | TYK2 (0.52) | TYK2P2RX7POLBKMT2AP2RY12 | |
| SCHEMBL4954916 | 0.81 | NPC1 (0.56) | KMT2AMAPTHTTNPSR1RAB9A | |
| SCHEMBL24001 | 0.81 | MAPT (0.66) | POLBKMT2AMAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117693511-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-2670754-B1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20160207893-A1 | NOVEL CALCIUM MODULATORS | MYOTHERIX, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160207893-A1 | NOVEL CALCIUM MODULATORS | MYOTHERIX, INC. | 2016-07-21 | — | — | US | disclosed |
| EP-2615092-B1 | HETEROCYCLIC AMINO BERBAMINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO LTD (CN) | 2015-08-26 | — | — | EP | disclosed |
| EP-2615092-B1 | HETEROCYCLIC AMINO BERBAMINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO LTD (CN) | 2015-08-26 | — | — | EP | disclosed |
| US-8987288-B2 | Heterocyclic aminoberbamine derivatives, the preparation process and use thereof | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2015-03-24 | — | — | US | disclosed |
| US-8987288-B2 | Heterocyclic aminoberbamine derivatives, the preparation process and use thereof | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2015-03-24 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1696920-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050261284-A1 | Diazinopyrimidines | CHEN JIAN J | 2005-11-24 | — | — | US | disclosed |
| US-6943158-B2 | Diazinopyrimidines | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1565475-A1 | DIAZINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005062795-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2004046152-A1 | DIAZINOPYRIMIDINES | F. HOFFMANN LA ROCHE AG (CH) | 2004-06-03 | — | — | WO | disclosed |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | HOFFMANN-LA ROCHE INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261284-A1 | Diazinopyrimidines | MAPK6, MAPK1, MAP2K6 | TYK2 304/4885P2RX7 297/4885POLB 3111/4885 |
| US-20160207893-A1 | NOVEL CALCIUM MODULATORS | CACNA1E, CASR, CACNA1D | TYK2 4060/4885P2RX7 1024/4885POLB 4862/4885 |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | TYK2 4631/4885P2RX7 4582/4885POLB 2001/4885 |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | FGFR1, MAPK1, FGF1 | TYK2 378/4885P2RX7 1170/4885POLB 3135/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | TYK2 1668/4885P2RX7 3194/4885POLB 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.